Apixaban No Better Than Aspirin for Treatment of Embolic Stroke of Undetermined Source | ASH Clinical News | American Society of Hematology
Leah Lawrence is a freelance health writer and editor based in Delaware. Use of the direct oral anticoagulant (DOAC) apixaban was not superior to cardiac monitoring-guided aspirin for the prevention of new ischemic lesions in a patient population with an enriched embolic stroke of undetermined source (ESUS), according to results of the ATTICUS study published in NEJM Evidence. In a multicenter, open-label, randomized study of patients with ESUS and at least one predictive factor for atrial fibrillation